Zach Reitano

Cory Weinberg, a finance expert, dives into Strava's confidential IPO and Lambda's impressive $350M raise. Dan Shipper, CEO of Every, reveals how AI is blurring lines between media and software, while offering insights on trust in AI agents. Zach Reitano, from Ro, discusses the launch of a new GLP-1 pill and how AI is reshaping healthcare delivery, emphasizing patient empowerment. The conversation also touches on Silicon Valley's obsession with biological age tests, contrasting hype with science, and examining the demand for anti-aging solutions.

Zach Reitano, CEO of telehealth platform Ro, discusses the booming GLP-1 drug marketplace and its economic implications. He highlights how these medications could transform obesity treatment by changing eating habits and healthcare dynamics. In contrast, Dr. Robert Lustig, an endocrinologist from UCSF, raises skepticism about their efficacy and long-term health impacts, emphasizing potential side effects like nausea. The conversation challenges traditional views on weight management and stresses the importance of equitable access and multifaceted treatment approaches.

Zach Reitano, entrepreneur focused on personalized healthcare, shares how Covid accelerated telemedicine adoption, the importance of building trust with patients, and the impact of Ro's commercial featuring his dad.

Zach Reitano, CEO and co-founder of Ro, a direct-to-patient healthcare company, discusses the challenges in today's healthcare model. He highlights how the system often overlooks patient needs and the importance of focusing on cost, quality, and access. Reitano shares insights into using technology to enhance care and argues that quality should not be equated with time spent. He champions a patient-centric approach, advocating for empowered health choices and innovative financial solutions like healthcare savings accounts to foster autonomy.

Zach Reitano, CEO of Ro, a telehealth platform that focuses on obesity treatment, dives into the monumental shift caused by weight-loss drugs like Ozempic. He discusses the skyrocketing demand for these medications and their ripple effects on society and healthcare. Reitano shares why obesity treatment became Ro's 'hero product' and compares the potential impact of GLP-1s to emerging technologies like AI. He also addresses the stigma surrounding obesity, emphasizing a need for patient-focused marketing and equitable access to treatments.